

PHARMACY POLICY STATEMENT

North Carolina Marketplace

DRUG NAME	Syfovre (pegcetacoplan)
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Syfovre, approved by the FDA in 2023, is a complement (C3) inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It is the first drug approved for this indication.

There are 2 types of AMD: dry or wet (neovascular). Syfovre is approved for dry AMD which is more common but progresses more slowly to vision loss than wet AMD. GA can occur in the intermediate and advanced stages of dry AMD and is caused by the breakdown of choroid, resulting in irreversible lesions that can impair vision or lead to blindness.

Approval of Syfovre was based on combined analysis of c(l)16(i)16(n)25(J TJ ET Q q 0.00000912 0 612 792 re

